BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma

• Joseph H. Jeong ,

  Contributed equally to this work with: Joseph H. Jeong, Zhenxiong Wang

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Zhenxiong Wang ,

  Contributed equally to this work with: Joseph H. Jeong, Zhenxiong Wang

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Alexander S. Guimaraes,

  Affiliations Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States of America

  ⨯
• Xuesong Ouyang,

  Affiliation Department of Urology and Pathology, Columbia University College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York, New York, United States of America

  ⨯
• Jose L. Figueiredo,

  Affiliations Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States of America

  ⨯
• Zhihu Ding,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Shan Jiang,

  Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Isil Guney,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

  ⨯
• Gyeong Hoon Kang,

  Affiliation Department of Pathology, Seoul National University College of Medicine, Seoul, Korea

  ⨯
• Eyoung Shin,

  Affiliation Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• William C. Hahn,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

  ⨯
• Massimo F. Loda,

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, United States of America

  ⨯
• Cory Abate-Shen,

  Affiliation Department of Urology and Pathology, Columbia University College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York, New York, United States of America

  ⨯
• Ralph Weissleder,

  Affiliations Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States of America, Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Lynda Chin

  * E-mail: lynda_chin@dfci.harvard.edu

  Affiliations Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America, Department of Dermatology, Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯